Work

A randomized clinical trial of chemotherapy with gemcitabine/cisplatin/nabpaclitaxel with or without the AXL inhibitor bemcentinib (BGB324) for patients with advanced pancreatic cancer.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.4_suppl.tps473

Authors: Muhammad Shaalan Beg, Andrew M. Lowy, Peter J. O'Dwyer, Gayle S. Jameson, Erkut Hasan Borazanci, Hitendra Patel, Clare Massey, Julia Schoelermann, James Lorens, Farjana Fattah, Kimberli Crane, Erin Fenske Williams, Jatan Clark, Daniel D. Von Hoff, Rolf A. Brekken

Institutions: The University of Texas Southwestern Medical Center, University of California San Diego, Moores Cancer Center, Abramson Cancer Center, University of Pennsylvania, HonorHealth, University of Arizona Cancer Center, BerGenBio (Norway), Harold C. Simmons Comprehensive Cancer Center, Translational Genomics Research Institute

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2914527137

Cites:

Cited by: 10

Related to: 10